

MENJONG SORIG PHARMACEUTICALS CORPORATION LTD.
THIMPHU, BHUTAN

STATEMENT OF COMPREHENSIVE INCOME
for the Quarter ended 31st March, 2023

PARTICULARS	Note No.	QUARTER ENDED	QUARTER ENDED
		31-03-2023	31-03-2022
		(Nu.)	(Nu.)
<u>REVENUE</u>			
Sales	15	11,612,490.30	11,612,490.30
Other Income	16	453,363.57	453,363.57
Total Revenue		12,065,853.87	12,065,853.87
<u>EXPENDITURE</u>			
Changes in Finished Goods & Work-in-Progress	17	885,091.90	885,091.90
Raw Materials & Packaging Materials Consumed	18	2,451,431.71	2,451,431.71
Manufacturing Expenses	19	486,067.37	486,067.37
Employee Benefit Expenses	20	5,934,961.00	5,934,961.00
Finance Cost	21	-	-
Depreciation & Amortization	01 & 02	2,212,358.62	2,212,358.62
Other Expenses	22	519,569.81	519,569.81
Total Expenditure		12,489,480.40	12,489,480.40
Profit/(Loss) before Tax		(423,626.53)	(423,626.53)
<u>Tax Expense</u>			
Current Tax		-	-
Net Profit/(Loss) for the Year		(423,626.53)	(423,626.53)
Other comprehensive income			
<i>Items that will not be reclassified to profit or loss</i>			
Remeasurements of post-employment benefit obligations		-	-
Income tax relating to above item		-	-
Other comprehensive income, net of tax		-	-
Total comprehensive income		(423,626.53)	(423,626.53)
Earnings per equity share			
Basic and diluted			
Notes on Financial Statements forms integral part of Accounts	20	(0.23)	(0.23)

This is the Statement of Comprehensive Income referred to in our report of even date.

Chairman

Chief Executive Officer

Director

Place : THIMPHU

Date : , 2022